Clinical trials: Hematopoietic
TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.
- Trial name
- NCT07094464
- Testing
- Maintenance Therapy with Selinexor and Azacitidine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Daihong Liu
Graft Versus Host Disease
Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults
The purpose of this study is to evaluate the presence and manifestations of ocular graft versus host disease in adults that had hematopoietic stem cell transplantation in the past 3 years at the sheba medical center, Israel.
- Trial name
- NCT00912067
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Sheba Medical Center
Allogeneic Hematopoietic Stem Cell Transplantation
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
This is a phase I/II study of MLN9708 for the prophylaxis of chronic graft-versus-host-disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT02250300
- Testing
- MLN9708 (2.3 mg), MLN9708 (4.0 mg), MLN9708 (3.0 mg)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mehdi Hamadani
Leukemia
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03759899
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma
Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma
1. Study Title A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma…
- Trial name
- AUTO-CAR-T (NCT06913192)
- Testing
- CAR-T
- Volunteers
- 50 people
- Sponsor
- Xuzhou Medical University
SCID, Omenn's Syndrome
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
- Conditions
- SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome
- Trial name
- NCT01652092
- Testing
- Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit
This study investigates the use electroencephalography (EEG - a test that measures brain waves) to learn if patients who appear unresponsive (do not respond to noises, words, or touch) retain any consciousness.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT05091632
- Testing
- Electroencephalography, Questionnaire Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease
The objective of this study is to investigate if up to two injections of plerixafor represent a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem progenitor cells (HSPC) for autologous…
- Trial name
- PISMO (NCT03664830)
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
The purpose of this study is to test how practical it is to use the Ultrasonic Cardiac Output Monitor (USCOM), an FDA-approved device, on oncology patients (specifically those with blood cancers).
- Conditions
- Leukemia, Lymphoma, Paraproteinemias, Multiple Myeloma
- Trial name
- NCT01755000
- Testing
- USCOM scan, Fluid Bolus
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Washington University School of Medicine
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
This randomized phase III trial is studying tacrolimus, methotrexate, and sirolimus to see how well they work compared to tacrolimus and methotrexate in preventing graft-versus-host disease in young patients who are undergoing…
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00382109
- Testing
- thiotepa, cyclophosphamide, tacrolimus
- Where
- 50 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Children's Oncology Group
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
This phase Ib/II trial studies side effects and best dose of inotuzumab ozogamicin and how well it works when given together with vincristine sulfate liposome in treating patients with CD22 positive (+) B-cell acute lymphoblastic…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive
- Trial name
- NCT03851081
- Testing
- Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Thrombosis, Venous, Bleeding Hemorrhage
Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer, after disease progression. VTE is increasingly recognized as a complication in patients with hematologic malignancies and various studies…
- Conditions
- Thrombosis, Venous, Bleeding Hemorrhage, Venous Thromboembolic Disease, Hematologic Malignancy
- Trial name
- NCT05396157
- Where
- Canada
- Volunteers
- 813 people
- Sponsor
- Mount Sinai Hospital, Canada
Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
Gut Decontamination In Pediatric Allogeneic Hematopoietic
This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD).
- Trial name
- NCT02641236
- Testing
- Vancomycin-polymyxin B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
This study will see if the researchers can lower that risk by giving the patient Palifermin. This drug helps protect the lining of the mouth, throat, and stomach.
- Trial name
- NCT00629798
- Testing
- Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT03328936
- Testing
- Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Kidney Failure Chronic, Stem Cell Transplant
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor…
- Conditions
- Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance
- Trial name
- NCT07358195
- Testing
- Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Myelodysplastic Syndrome
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a "phase I trial," in which a preset schedule of doses gets more powerful for each new group of patients as the…
- Trial name
- NCT00672165
- Testing
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft vs Host Disease
Pediatric cGVHD Symptom Scale
Background: Some children/adolescents who have had a stem cell transplant live with chronic graft-versus-host-disease (cGVHD). cGVHD is a side effect of the transplant that can cause multiple bothersome symptoms and negatively…
- Trial name
- NCT04044365
- Where
- 17 sites in United States, Canada
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myeloid Neoplasm
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with acute myeloid leukemia or other…
- Trial name
- NCT04195945
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation
The MAC-HAPLO-MUD trial is a randomized prospective phase III trial comparing HLA 10/10 matched unrelated donor and haploidentical allogeneic hematopoietic stem cell transplantation after myeloablative conditioning regimen in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myeloproliferative Syndromes, Myelodysplastic Syndromes
- Trial name
- MacHaploMud (NCT03655145)
- Testing
- Haplo donor stem cell transplantation, HLA 10/10 MUD stem cell transplantation
- Volunteers
- 344 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.